Otsuka adds Phase 3 data to Voyxact’s IgA nephropathy case
CURRENT BRIEF VERSION: Otsuka said new Phase 3 VISIONARY data support Voyxact (sibeprenlimab-szsi) in adults with primary IgA nephropathy, adding to the evidence base behind the drug’s November 2025 FDA accelerated approval. The approval was based on interim VISIONARY results showing a placebo-adjusted 51% reduction in proteinuria at nine months, and Otsuka later reported 12-month findings showing a 54.3% placebo-adjusted reduction in geometric mean 24-hour UPCR. Voyxact is an APRIL-targeting monoclonal antibody, and the ongoing confirmatory portion of VISIONARY is designed to test whether that proteinuria benefit translates into slower eGFR decline over about 24 months. Otsuka’s update also lands as the company continues broader pipeline expansion efforts, including a deal to acquire Transcend Therapeutics for about $1.225 billion to add TSND-201, a Phase 3-ready PTSD candidate, to its neuropsychiatric portfolio. (otsuka-us.com; PharmaShots)
Why it matters: For veterinary professionals, this is mainly a translational medicine and drug-development signal rather than a practice-changing animal health story. IgA nephropathy is a human kidney disease, but the Voyxact program is another example of how targeted immunology, surrogate endpoints, and accelerated approval pathways are shaping nephrology drug development. The key question now is the same one clinicians and regulators often face across species: whether an early biomarker win, here proteinuria reduction, will hold up as meaningful long-term organ protection. Otsuka’s parallel business-development activity also underscores how large companies are balancing specialty renal programs with expansion in other therapeutic areas. (otsuka.co.jp; PharmaShots)
What to watch: Watch for the final VISIONARY readout on eGFR slope, expected with study completion in late 2026, because that confirmatory outcome is likely to determine Voyxact’s long-term regulatory standing and clinical positioning. Separately, Otsuka said its Transcend acquisition is expected to close in Q2 2026, adding another marker of how aggressively the company is building its late-stage pipeline. (clinicaltrials.gov; PharmaShots)